Indoxyl Sulfate Elimination in Renal Replacement Therapy: Influence of Citrate- versus Acetate-Buffering Component during Bicarbonate Dialysis

Abstract EN

Indoxyl sulfate has been identified as a major factor in the dysregulation of several genes.

It is classified as a poorly dialyzable uremic toxin and thus a leading cause in the poor survival rate of dialysis patients.

A monocentric, prospective, open cohort study was performed in 43 male patients undergoing chronic renal replacement therapy in a single hemodialysis center.

The aim of the study was to determine the influence of acetate- versus citrate-buffered dialysis fluids in hemodialysis (HD) and postdilution hemodiafiltration (HDF) settings on the elimination of indoxyl sulfate.

Also, additional factors potentially influencing the serum concentration of indoxyl sulfate were evaluated.

For this purpose, the predialysis and postdialysis concentration ratio of indoxyl sulfate and total protein was determined.

The difference was of 1.15 (0.61; 2.10), 0.89 (0.53; 1.66), 0.32 (0.07; 0.63), and 0.44 (0.27; 0.77) μmol/g in acetate HD and HDF and citrate HD and HDF, respectively.

Acetate HD and HDF were superior when concerning IS elimination when compared to citrate HD and HDF.

Moreover, residual diuresis was determined as the only predictor of lower indoxyl sulfate concentration, suggesting that it should be preserved as long as possible.

This trial is registered with EU PAS Register of Studies EUPAS23714.